Splenic irradiation as palliative treatment for symptomatic @entity381 due to secondary XXXX : a multi-institutional experience.

@entity1 @entity137 @entity417 @entity11998 @entity4558 @entity4018 @entity381 @entity158 @entity1860
PURPOSE: To evaluate the impact of @entity4558 irradiation as a palliative treatment for symptomatic @entity381 due to secondary @entity4018 . METHODS: Seventeen @entity1 with @entity1860 and 3 with idiopathic @entity11998 presented with @entity381 , @entity158 and @entity417 . Due to symptomatic @entity381 , despite first-line treatment, the @entity1 underwent @entity4558 irradiation. Two @entity1 received two different schedules of external radiotherapy (580 cGy in 5 fractions and 600 cGy in 6 fractions). Eight @entity1 received 980 cGy in 14 fractions. Ten @entity1 received two courses of 360 cGy in 6 fractions, 3 months apart. Median follow-up was 12 months post irradiation. RESULTS: The @entity1 showed excellent response to treatment one month post-radiotherapy, while treatment was well tolerated without severe @entity137 . The dimensions of the spleen decreased significantly. @entity158 -related Visual Analogue Score (VAS) regressed after completion of irradiation. During 12-month follow-up all @entity1 maintained the benefit of radiotherapy. CONCLUSION: This study indicates that @entity4558 irradiation could be a safe and effective palliative treatment for symptomatic @entity381 due to secondary @entity4018 .
